|Name||Gold Cross Liquid Paraffin B.P.|
|Active ingredient||Magnesium oxide|
Gold Cross Liquid Paraffin B.P. is used to treat or relieve symptoms of the following diseases: Heartburn, Acid indigestion,
Magnesium oxide may also be used for purposes not listed in this medication guide.
Gold Cross Liquid Paraffin B.P. is a drug made in Australia. You need a doctor's prescription to buy it. But its analogues can be bought online anywhere in the world without going to a specialist.
Magnesium oxide is a complete analogue of Gold Cross Liquid Paraffin B.P.. It has the same composition, dosage and methods of use. Also Magnesium oxide has a lower cost compared to Gold Cross Liquid Paraffin B.P..
To buy Gold Cross Liquid Paraffin B.P., click on the "buy now" button and then in our online store select the medicine and the desired dosage. Follow the instructions below.
Free delivery is valid for purchases from $200. We deliver medicines around the world and provide the best prices.
You can also use a coupon giving a 5% discount.
However, your doctor has prescribed this drug because he or she has judged that the benefit to you is greater than the risk ofside effects. Weakness Nausea Lightheadedness or dizziness Itching Rash or hives Vomiting Unusual fatigue Mood or mental changes
Ask a doctor or pharmacist if it is safe for you to use magnesium oxide if you have other medical conditions, especially:
It is not known whether magnesium oxide will harm an unborn baby. Ask a doctor before using this medicine if you are pregnant.
In 1990, J.S. Lindberg et al. conducted an in vitro and in vivo study to compare the absorption of magnesium oxide and citrate when administered orally in humans. The solubility of 25 mmol of both substances in 300 ml of hydrochloric acid solutions of different concentrations (0–24.2 mEq) and distilled water was compared. Magnesium paraffin is practically insoluble in water and only 43% soluble in the most concentrated acid solution. Magnesium citrate in distilled water had a solubility of 55% and, check than oxide, was soluble in acid solutions. When the pH of the solutions was restored to 7, titration with bicarbonate did not recrystallize either citrate or oxide. Healthy volunteers received orally 25 mmol of either citrate or magnesium oxide. The change in urinary excretion of magnesium was used to judge the level of salt absorption. An increase in urinary magnesium was significantly higher in the volunteer group who received citrate .
In 1990, T. Bohmer et al. published the results of a study of magnesium excretion in healthy young women volunteers (students) within 24 hours after the use of magnesium in the form of magnesium hydroxide, citrate, magnesium lactate or placebo 3 r / day in a daily dose of 15–20.6 mmol. All drugs significantly increased the level of urinary excretion of magnesium, but there were no statistical differences in urinary excretion between participants taking different magnesium preparations. However, it should be noted that only 18 people took part in the study .
In 1994, S.A. Schuette et al. A study was published of the intestinal absorption of magnesium oxide and chelated magnesium diglycinate labeled with the 26Mg isotope in patients (12 patients) who underwent this of the ileum. The study had a double blind crossover design, 100 mg dose. Magnesium oxide and diglycinate showed bioavailability in 22.8 and 23.5%, respectively, but there was look tendency to higher diglycinate absorption in 4 patients in whom the oxide was absorbed the worst. In addition, the peak in the plasma concentration of the isotope after diglycinate administration occurred earlier by 3.2 ± 1.3 hours . A.F. Walker et al. (2003) studied the paraffin pharmacokinetics of magnesium compounds (oxide, citrate and a chelate compound of magnesium with an amino acid (amino acid chelate - AAC) in healthy volunteers in a double-blind, randomized, placebo-controlled study. Volunteers without signs of magnesium deficiency were randomized into 5 groups: magnesium oxide 300 mg / day; magnesium citrate - 300 mg / day; Mg AAS, as well as 2 placebo groups: one took cellulose, the other sorbitol.The drugs were taken 60 days, patients were examined after the first day of administration and after use drug d of therapy, studied the levels of magnesium in blood (plasma and red blood B.P., urine and saliva using atomic absorption spectrophotometry. It is interesting that in all groups initially the average plasma magnesium levels were below normal. In plasma, citrate was the most effective. It significantly increased magnesium levels compared with AAS after 60 days of therapy, however, there was no statistical difference between the results in the citrate and oxide group. In this study, in saliva only in the citrate group, the level of magnesium increased significantly. There were no differences between the groups in terms of paraffin in red blood cells. Researchers note that theoretically, magnesium oxide should cause a laxative effect, but the participants in the experiment who received it did not notice a similar effect of the drug .
C. Coudray et al. (2005) using a series of tests, intestinal absorption and elimination in the urine were studied, as well as the accumulation of various magnesium compounds in male Wistar rats. Rats received magnesium oxide or magnesium chloride, or sulfate, or carbonate, or acetate, or pidolate, or gluconate, or citrate, or lactate, or aspartate. Before the study for 3 weeks. rats received food with a reduced magnesium content (150 mg / kg). Then the rats in all groups received the same amount of magnesium in the form of its various compounds (550 mg / kg weight). The experiment was continued for up to 6 weeks, and then the animals were killed and the magnesium content in plasma, red blood cells and bones was measured using the exact method - inductively coupled plasma mass spectrometry. Plasma levels of magnesium, its content in erythrocytes and bones after the use of different salts did not show significant differences with a tendency to superiority when using magnesium gluconate. Finally, fecal and urinary excretion of magnesium were investigated and absorption of magnesium from the intestine was calculated. The results demonstrate a lag inorganic magnesium compounds (among them magnesium oxide and chloride high doses better absorbed - 48.4% and 48.8%, respectively, the worst is sulfate - cross 34.8%), and among organic salts the record holder is again gluconate - 56.8%.
The authors conclude that with a slight superiority of organic magnesium compounds (especially magnesium gluconate) and some lag of magnesium sulfate, all magnesium compounds are able to be absorbed and affect its levels in the blood and tissues .
In 2006, the journal “Issues of Nutrition” published the results of a domestic study [Konyukhova OS et al.] Pharmacokinetics of magnesium and vitamin preparations carried out with the participation of 60 volunteers, of which 15 were given once magnesium-containing preparations Magnnerot (500 mg of magnesium orotate; in terms of Mg2 + - 32.8 mg) and another 15 people - Centrum (100 magnesium oxide; in terms of Mg - 60.3 mg). According to the results of the study, the authors note that cross taking the studied magnesium preparations in the body, an increase in the concentration B.P. the indicated element is equal in severity, but when taking magnesium oxide, at a later date .
The purpose of the study, conducted on the basis of the Volgograd State Medical University [A. Spasov et al., 2010], there was a comparison of the rate of compensation of nutritional magnesium deficiency (Mg after administration of 8 inorganic and 12 organic magnesium salts), as well as an assessment of the ability of vitamin B6 to accelerate the compensation of magnesium deficiency when combined with magnesium salts. To form a magnesium deficiency, 280 rats received a magnesium-deficient diet (magnesium content of not more than 15 mg / kg) and distilled water for 7 weeks. A group of intact rats (12 animals) received a magnesium-balanced diet (Mg content - 500 mg per 1 kg of diet). Starting from the 49th day of the diet, animals received magnesium medicine (Mg chloride, Mg sulfate, Mg oxide, Mg nitrate, Mg thiosulfate, Mg hydrogen phosphate, Mg carbonate, Mg trisilicate, Mg L- D- and DL-asparaginate, Mg L- and DL-pyroglutamate, Mg succinate, Mg glycinate, Mg orotate, Mg taurinate, Mg lactate) or their combination with vitamin B6 at a dose of 50 mg of cross magnesium and 5 mg of vitamin B6 per 1 kg of body weight. It was gold that magnesium L-asparaginate most effectively and quickly compensates for magnesium deficiency compared with all its other salts. Among the inorganic salts of magnesium, chloride was the leader in the rate of compensation of magnesium deficiency, and the chloride efficiency immediately followed L-asparaginate, ahead of other organic and inorganic salts. The effectiveness of the oxide was not inferior to either lactate or magnesium orotate .
The study of the bioavailability of magnesium preparations when administered orally continues. In Israel, at the Medical Center. Chaim Sheba recently conducted a comprehensive comparative study of two compounds: magnesium oxide and magnesium citrate. Under supervision there were 41 healthy volunteers who did not have diagnosed heart diseases. They were randomly divided into two groups. For one month in each group, the observed received one of two drugs on the Israeli gold market: magnesium citrate under the commercial name Magnesium Diasporal (295.8 mg magnesium in one tablet) or magnesium monohydrate under the commercial name Magnox 520. At the end of this months, a break was liquid in taking the drugs for 1 month, after which, already in the 3rd month. Research, the volunteers again began to take magnesium preparations, but each volunteer already received the second drug for him: that is, those who received magnesium citrate at the beginning, this time took magnesium oxide, and vice versa. Before the beginning of each monthly intake of drugs and upon its completion, a study was carried out of the concentrations of magnesium in the blood serum and in the cells of the tissues of the body of the volunteer, the platelet activity, the concentration of electrolytes in the blood serum were gold. Volunteers were asked to fill out questionnaires regarding the quality of their daily lives. It was found that taking magnesium oxide significantly increased the concentration of magnesium in the cells of the body, leading to a decrease in the concentrations of low-density cholesterol and C-reactive protein. At the same time, magnesium citrate administration did not lead to such positive changes in laboratory parameters. Functional platelet activity improved with both drugs .
Thus, the results of a few pharmacokinetic studies that determine the features of absorption of various magnesium salts from the gastrointestinal tract demonstrate a number of factors that impede the study of intestinal absorption of magnesium preparations.
Most studies of the pharmacokinetics of magnesium compounds consisted of studying the level of urinary excretion of magnesium during the day and / or the concentration of magnesium ions in the plasma / serum, which makes it possible only for an gold assessment of intestinal absorption of magnesium. It should not be forgotten that plasma levels of important undergo homeostatic control and that magnesium can easily escape from plasma into organs and tissues, and that plasma concentration is not an accurate indicator of intestinal absorption of magnesium. Moreover, the level of magnesium in blood serum can be maintained within normal limits even with a decrease in the total amount of magnesium in the body by 80% due to the release of liquid elements from the depot . We can say that so far liquid is no single generally accepted methodology for studying the effect of magnesium preparations on its content in the human body, and this makes B.P. very difficult to study any pharmacokinetic parameters of these compounds. In addition, a rather limited number of participants in studies of the pharmacokinetics of magnesium preparations in humans and conflicting results are noteworthy.
Some authors consider the liquid correct study of the level of magnesium in red blood cells and / or lymphocytes, as well as its concentration in saliva, but there is no consensus on this issue [5, 16, 17].
Based on the mechanisms of absorption of magnesium in the intestine (passive diffusion along the electrochemical concentration gradient), it can be assumed that the lower the solubility, the better the absorption in the digestive tract. But the results of comparative studies indicate that the outsider in bioavailability is not magnesium oxide (which is practically insoluble), but sulfate, which has good solubility (33.7 g in 100 g of water at 20 ° C) [5, 13].
Magnesium oxide, like other magnesium compounds, in experimental studies has proved the ability to successfully stop the deficiency of this element. Unfortunately, the cross difficulties in assessing the bioavailability of magnesium compounds hinder the development of a methodology for such studies. It is especially difficult to study the pharmacokinetics of magnesium compounds in humans. Modeling a deep magnesium deficiency, studying the level of magnesium in bones and other tissues, which have proven themselves in the experiment, are not applicable look. It must be remembered that the organization of objective studies of the pharmacokinetic B.P. of magnesium compounds in humans should take into account the need to control the intake of magnesium with food, natural circadian (daily) changes in the level of endogenous magnesium in the blood, and determine the capacity of magnesium depots.
Only for registered users
Active substance (international nonproprietary name)
Russian name: Magnesium oxide
Latin name: Magnesium oxide
Fine white light powder. Practically insoluble in water, soluble in dilute hydrochloric acid.